Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference
Pasithea Therapeutics (NASDAQ: KTTA) has announced its participation in the upcoming 2025 CAGLA NeauxCancer Conference, a leading global oncology forum scheduled for March 27-29, 2025, in New Orleans.
The company's Vice President of Business Development, Mathew Lazarus, will present on March 28 at 11:00 AM CDT at The Roosevelt Hotel. His presentation will focus on PAS-004, the company's next-generation macrocyclic MEK inhibitor being developed for neurofibromatosis type 1 (NF1) and other cancer indications.
The presentation will include interim data from their ongoing Phase 1 study, covering safety, tolerability, and pharmacokinetic (PK) results in advanced cancer patients with MAPK pathway-driven tumors. Lazarus will also discuss Pasithea's progress in clinical development and their strategy to revolutionize cancer and NF1 treatment.
Pasithea Therapeutics (NASDAQ: KTTA) ha annunciato la sua partecipazione alla prossima 2025 CAGLA NeauxCancer Conference, un importante forum globale di oncologia in programma dal 27 al 29 marzo 2025 a New Orleans.
Il Vice Presidente dello Sviluppo Commerciale dell'azienda, Mathew Lazarus, presenterà il 28 marzo alle 11:00 AM CDT presso il Roosevelt Hotel. La sua presentazione si concentrerà su PAS-004, l'inibitore MEK di nuova generazione sviluppato per la neurofibromatosi di tipo 1 (NF1) e altre indicazioni oncologiche.
La presentazione includerà dati intermedi del loro studio di Fase 1 in corso, che copriranno la sicurezza, la tollerabilità e i risultati farmacocinetici (PK) in pazienti oncologici avanzati con tumori guidati dalla via MAPK. Lazarus discuterà anche dei progressi di Pasithea nello sviluppo clinico e della loro strategia per rivoluzionare il trattamento del cancro e della NF1.
Pasithea Therapeutics (NASDAQ: KTTA) ha anunciado su participación en la próxima 2025 CAGLA NeauxCancer Conference, un importante foro global de oncología programado para el 27 al 29 de marzo de 2025 en Nueva Orleans.
El Vicepresidente de Desarrollo Comercial de la empresa, Mathew Lazarus, presentará el 28 de marzo a las 11:00 AM CDT en el Roosevelt Hotel. Su presentación se centrará en PAS-004, el inhibidor MEK de próxima generación que se está desarrollando para la neurofibromatosis tipo 1 (NF1) y otras indicaciones oncológicas.
La presentación incluirá datos intermedios de su estudio de Fase 1 en curso, que abarcarán la seguridad, la tolerabilidad y los resultados farmacocinéticos (PK) en pacientes con cáncer avanzado con tumores impulsados por la vía MAPK. Lazarus también discutirá el progreso de Pasithea en el desarrollo clínico y su estrategia para revolucionar el tratamiento del cáncer y la NF1.
Pasithea Therapeutics (NASDAQ: KTTA)는 2025년 3월 27일부터 29일까지 뉴올리언스에서 열리는 세계적인 종양학 포럼인 2025 CAGLA NeauxCancer Conference에 참가한다고 발표했습니다.
회사의 사업 개발 부사장인 Mathew Lazarus는 3월 28일 오전 11시 CDT에 루즈벨트 호텔에서 발표할 예정입니다. 그의 발표는 제1형 신경섬유종증(NF1) 및 기타 암 적응증을 위해 개발 중인 차세대 매크로사이클 MEK 억제제인 PAS-004에 초점을 맞출 것입니다.
발표에는 MAPK 경로에 의해 유도된 종양을 가진 진행성 암 환자들에 대한 안전성, 내약성 및 약물 동태(PK) 결과를 포함한 진행 중인 1상 연구의 중간 데이터가 포함될 것입니다. Lazarus는 또한 Pasithea의 임상 개발 진행 상황과 암 및 NF1 치료를 혁신할 전략에 대해 논의할 것입니다.
Pasithea Therapeutics (NASDAQ: KTTA) a annoncé sa participation à la prochaine 2025 CAGLA NeauxCancer Conference, un forum mondial de premier plan en oncologie prévu du 27 au 29 mars 2025 à La Nouvelle-Orléans.
Le vice-président du développement commercial de l'entreprise, Mathew Lazarus, présentera le 28 mars à 11h00 CDT à l'hôtel Roosevelt. Sa présentation portera sur PAS-004, l'inhibiteur MEK de nouvelle génération en cours de développement pour la neurofibromatose de type 1 (NF1) et d'autres indications cancéreuses.
La présentation comprendra des données intermédiaires de leur étude de phase 1 en cours, couvrant la sécurité, la tolérabilité et les résultats pharmacocinétiques (PK) chez des patients atteints de cancer avancé avec des tumeurs conduites par la voie MAPK. Lazarus discutera également des progrès de Pasithea dans le développement clinique et de leur stratégie pour révolutionner le traitement du cancer et de la NF1.
Pasithea Therapeutics (NASDAQ: KTTA) hat seine Teilnahme an der bevorstehenden 2025 CAGLA NeauxCancer Conference angekündigt, einem führenden globalen Onkologie-Forum, das vom 27. bis 29. März 2025 in New Orleans stattfinden wird.
Der Vizepräsident für Geschäftsentwicklung des Unternehmens, Mathew Lazarus, wird am 28. März um 11:00 Uhr CDT im Roosevelt Hotel präsentieren. Sein Vortrag wird sich auf PAS-004 konzentrieren, den next-generation makrozyklischen MEK-Hemmer, der für Neurofibromatose Typ 1 (NF1) und andere Krebsindikationen entwickelt wird.
Die Präsentation wird Zwischenberichte aus ihrer laufenden Phase-1-Studie enthalten, die Sicherheit, Verträglichkeit und pharmakokinetische (PK) Ergebnisse bei fortgeschrittenen Krebspatienten mit MAPK-Weg-gesteuerten Tumoren abdecken. Lazarus wird auch über die Fortschritte von Pasithea in der klinischen Entwicklung und deren Strategie zur Revolutionierung der Krebs- und NF1-Behandlung sprechen.
- None.
- None.
-- Conference taking place on March 27-29, 2025 in New Orleans --
-- CAGLA NeauxCancer Conference is a leading global forum in oncology --
MIAMI, March 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced its Vice President of Business Development, Mathew Lazarus, will be presenting at the 2025 Cancer Advocacy Group of Louisiana ("CAGLA") NeauxCancer Conference taking place on March 27-29, 2025 at the The Roosevelt Hotel in New Orleans.
Mr. Lazarus’s presentation will provide an overview of Pasithea’s next generation macrocyclic MEK inihibitor, PAS-004, including interim safety, tolerability and pharmacokinetic (PK) data from the Company’s ongoing open-label dose escalation Phase 1 study in advanced cancer patients with MAPK pathway-driven advanced tumors. He will discuss the Company's latest progress in clinical development and how Pasithea is advancing its next-generation molecule to transform cancer and NF1 treatment.
Details of the presentation are as follows:
Event: 2025 CAGLA NeauxCancer Conference
Date: March 28, 2025
Time: 11:00 AM CDT
Location: The Roosevelt New Orleans
Webcast: CAGLA 2025 Livestreams
The CAGLA NeauxCancer Conference is a premier gathering of leading oncology researchers, industry executives, and medical professionals focused on groundbreaking developments in cancer treatment and care.
For more information about the conference, visit https://cag-la.org/neauxcancer-2025/.
About Pasithea Therapeutics Corp.
Pasithea is a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. With an experienced team of experts in the fields of neuroscience, translational medicine, and drug development, Pasithea is developing new molecular entities for the treatment of neurological disorders, including Neurofibromatosis type 1 (NF1), Solid Tumors, and Amyotrophic Lateral Sclerosis (ALS). For more information, visit www.pasithea.com.
Pasithea Therapeutics Contact
Patrick Gaynes
Corporate Communications
pgaynes@pasithea.com
FAQ
What will Pasithea Therapeutics (KTTA) present at the 2025 CAGLA NeauxCancer Conference?
When and where is KTTA's presentation at the 2025 CAGLA Conference?
What medical conditions is KTTA's PAS-004 being developed to treat?
What type of drug is Pasithea's (KTTA) PAS-004?
What clinical stage is KTTA's PAS-004 currently in?
